成大生物 (688739)
Liaoning Chengda Biotechnology Co., Ltd.
K-Line Chart
No K-line data available
Company NameLiaoning Chengda Biotechnology Co., Ltd.
Listing Date2021-10-28
Issue Price110RMB
Registered Capital4164510k RMB
Legal RepresentativeLi Ning
Registered AddressNo. 1 Xinfang Street, Hunnan New District, Shenyang City, Liaoning Province
IndustryBiological Products
Main BusinessResearch, development, production, and sales of human vaccines
Company ProfileLiaoning Chengda Biotechnology Co., Ltd. has established production workshops for human rabies vaccine and Japanese encephalitis vaccine bulk products, as well as vaccine filling workshops. All operational workshops have passed the national new GMP certification. Additionally, the company is constructing a new plant in Benxi as a production base for some new varieties. The company focuses on the vaccine industry, consistently adhering to the core values of 'Integrity and Honesty, Benevolence and Harmony,' and upholding the philosophy of 'When Facing Life, Only Responsibility Matters.' It is committed to the research, development, production, and promotion of biological products that are domestically leading and internationally competitive. In the future, the company will continue to adhere to an innovation-driven, product-led, specialization-guaranteed, and efficiency-winning sustainable development strategy. It will prioritize public health, strictly control product quality, further improve social responsibility management, concentrate on the field of human vaccines, build intelligent workshops, enhance production efficiency, and continuously develop innovative products. The company aims to contribute to the development of China's biological products industry and implement the national strategies for innovation and high-quality development.
Stock Details
1. Key Indicators
- Total Shares(W): 41645.00
- Circulating A-Shares(W): 41645.00
- Earnings Per Share(RMB): 0.4000
- Net Assets Per Share(RMB): 22.5410
- Operating Revenue(W RMB): 109588.66
- Total Profit(W RMB): 21114.75
- **Net Profit Attributable to Parent(W RMB) **: 16481.20
- Net Profit Growth Rate(%): -50.01
- Weighted Return on Equity(%): 1.7400
- Operating Cash Flow Per Share(RMB): 0.4110
- Undistributed Profit Per Share(RMB): 9.3387
- Capital Reserve Per Share(RMB): 12.0883
2. Main Business
The main business covers:
- Research, development, production, and sales of human vaccines
3. Company Basic Information
- Company Name: Liaoning Chengda Biotechnology Co., Ltd.
- Listing Date: 2021-10-28
- Industry: Pharmaceutical Manufacturing
- Address: No. 1 Xinfang Street, Hunnan New District, Shenyang City, Liaoning Province
- Website: https://www.cdbio.cn
- Company Profile: The company was established by transforming Chengda Co., Ltd. into a joint stock limited company as of the base date of October 31, 2010, based on the audited net asset value.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Liaoning Chengda Co., Ltd. | Corporate Legal Person | 22766.38 | 54.67 |
| 2 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 191.24 | 0.46 |
| 3 | Southern China Securities 1000 ETF | Fund | 190.11 | 0.46 |
| 4 | Shanghai Orient Securities Innovation Investment Co., Ltd. | Corporate Legal Person | 170.00 | 0.41 |
| 5 | Penghua SSE STAR Market 100 ETF | Fund | 125.57 | 0.30 |
| 6 | Bosera SSE STAR Market 100 ETF | Fund | 119.83 | 0.29 |
| 7 | ChinaAMC China Securities 1000 ETF | Fund | 113.19 | 0.27 |
5. Concept Sectors
- Biological Vaccines
- Margin Trading & Securities Lending
- Share Buyback Plan
- Below IPO Price
- High Dividend Stocks
- SSE Governance
- STAR Market Biotech
- STAR Market 100
- SSE 580
Remarks
- Data update date: 2025-11-03
- Data source: Public Market Information